GPN Vaccines develops vaccines to protect adults and children from bacterial pathogens.

GPN Vaccines

GPN Vaccines is a clinical-stage company focused on creating innovative vaccines that offer robust protection against the world's most important bacterial pathogens.

Government of South Australia

National Health and Medical Research Council

Forepont Capital Partners

We are delighted to support Carla Gallasch as the University of Adelaide's first PhD student to be awarded a National Industry PhD Program Scholarship! 

Building on years of know how and learnings from the Gamma-PN program, Carla is working on a new vaccine to provide protection against Haemophilus influenzae - a major cause of ear infections in children.

GPN Vaccines is building its clinical team and is seeking an experienced Clinical Project Manager to work with our Chief Medical Officer. 

The role can be either full or part-time depending on experience and remote candidates are encouraged to apply. 

Industry experience is essential, and those with GCP training and a track record of running vaccine studies will be highly regarded.

Team lunches are getting bigger at GPN Vaccines! 

Celebrating the retirement of Professor James Paton and Leigh Willis who have both made invaluable contributions to the company, and welcoming new staff and students Chloe Gates, Ricky Williams, Brooke Dilmetz, Janice Henrichs and Mariana Couto Moniz.

We are pleased to announce the award of AUD$936,000 to GPN Vaccines in Round 3 of the CUREator Program! 

This funding will be used to support investigation of the durability of Gamma-PN's immune response in adults. 

Thank you to Brandon Capital and supporters CSIRO and Australian Government Department of Health and Aged Care for this important funding.

Congratulations Chloe Gates and welcome (officially) to the team! We look forward to building on the great work you did with us during your PhD as well as working on some exciting new projects!

We are humbled to have been invited to write a short review paper for Vaccine Insights recently titled 'Whole-cell pneumococcal vaccines: a future-proof approach to overcoming serotype replacement". 

Take a look if you are interested in learning more about our approach. 

Thanks for the opportunity BioInsights!

Metric
Company Name	GPN Vaccines
Symbol
MSH ID	COM:GPNVACCINES
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	AU
Stage
Employee Count	21
Website	gpnvaccines.com
LinkedIn	gpnvaccines
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

GPNV

COM:GPNVACCINES

GPN Vaccines

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue